Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Established and emerging uses of 5-ALA in the brain: an overview.

Díez Valle R, Hadjipanayis CG, Stummer W.

J Neurooncol. 2019 Feb;141(3):487-494. doi: 10.1007/s11060-018-03087-7. Epub 2019 Jan 3. Review.

PMID:
30607705
2.

Impact of 5-aminolevulinic acid fluorescence-guided surgery on the extent of resection of meningiomas--with special regard to high-grade tumors.

Cornelius JF, Slotty PJ, Kamp MA, Schneiderhan TM, Steiger HJ, El-Khatib M.

Photodiagnosis Photodyn Ther. 2014 Dec;11(4):481-90. doi: 10.1016/j.pdpdt.2014.07.008. Epub 2014 Aug 10.

PMID:
25117928
3.

A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas.

Lau D, Hervey-Jumper SL, Chang S, Molinaro AM, McDermott MW, Phillips JJ, Berger MS.

J Neurosurg. 2016 May;124(5):1300-9. doi: 10.3171/2015.5.JNS1577. Epub 2015 Nov 6.

PMID:
26544781
4.

Impact of the combination of 5-aminolevulinic acid-induced fluorescence with intraoperative magnetic resonance imaging-guided surgery for glioma.

Tsugu A, Ishizaka H, Mizokami Y, Osada T, Baba T, Yoshiyama M, Nishiyama J, Matsumae M.

World Neurosurg. 2011 Jul-Aug;76(1-2):120-7. doi: 10.1016/j.wneu.2011.02.005.

PMID:
21839963
5.
6.

What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?

Hadjipanayis CG, Widhalm G, Stummer W.

Neurosurgery. 2015 Nov;77(5):663-73. doi: 10.1227/NEU.0000000000000929. Review.

7.

5-ALA and FDA approval for glioma surgery.

Hadjipanayis CG, Stummer W.

J Neurooncol. 2019 Feb;141(3):479-486. doi: 10.1007/s11060-019-03098-y. Epub 2019 Jan 14. Review.

PMID:
30644008
8.

5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas.

Chohan MO, Berger MS.

J Neurooncol. 2019 Feb;141(3):517-522. doi: 10.1007/s11060-018-2956-8. Epub 2018 Aug 10. Review.

PMID:
30097823
9.

Endoscopic-assisted visualization of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery: a technical note.

Rapp M, Kamp M, Steiger HJ, Sabel M.

World Neurosurg. 2014 Jul-Aug;82(1-2):e277-9. doi: 10.1016/j.wneu.2013.07.002. Epub 2013 Jul 16.

PMID:
23871813
10.

5-Aminolevulinic acid fluorescence guided resection of malignant glioma: Hong Kong experience.

Chan DTM, Yi-Pin Sonia H, Poon WS.

Asian J Surg. 2018 Sep;41(5):467-472. doi: 10.1016/j.asjsur.2017.06.004. Epub 2017 Aug 26.

11.

Image guided surgery for the resection of brain tumours.

Barone DG, Lawrie TA, Hart MG.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD009685. doi: 10.1002/14651858.CD009685.pub2. Review.

PMID:
24474579
12.

Quantitative fluorescence using 5-aminolevulinic acid-induced protoporphyrin IX biomarker as a surgical adjunct in low-grade glioma surgery.

Valdés PA, Jacobs V, Harris BT, Wilson BC, Leblond F, Paulsen KD, Roberts DW.

J Neurosurg. 2015 Sep;123(3):771-80. doi: 10.3171/2014.12.JNS14391. Epub 2015 Jul 3.

13.

Fluorescence-guided surgery for high-grade gliomas.

Lakomkin N, Hadjipanayis CG.

J Surg Oncol. 2018 Aug;118(2):356-361. doi: 10.1002/jso.25154. Epub 2018 Aug 19. Review.

PMID:
30125355
14.

Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence.

Ewelt C, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, Stoffels G, Stummer W.

Clin Neurol Neurosurg. 2011 Sep;113(7):541-7. doi: 10.1016/j.clineuro.2011.03.008. Epub 2011 Apr 20.

PMID:
21507562
15.

Improving the extent of malignant glioma resection by dual intraoperative visualization approach.

Eyüpoglu IY, Hore N, Savaskan NE, Grummich P, Roessler K, Buchfelder M, Ganslandt O.

PLoS One. 2012;7(9):e44885. doi: 10.1371/journal.pone.0044885. Epub 2012 Sep 26.

16.

Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study.

Nabavi A, Thurm H, Zountsas B, Pietsch T, Lanfermann H, Pichlmeier U, Mehdorn M; 5-ALA Recurrent Glioma Study Group.

Neurosurgery. 2009 Dec;65(6):1070-6; discussion 1076-7. doi: 10.1227/01.NEU.0000360128.03597.C7.

PMID:
19934966
17.

Cadherin 13 overexpression as an important factor related to the absence of tumor fluorescence in 5-aminolevulinic acid-guided resection of glioma.

Suzuki T, Wada S, Eguchi H, Adachi J, Mishima K, Matsutani M, Nishikawa R, Nishiyama M.

J Neurosurg. 2013 Nov;119(5):1331-9. doi: 10.3171/2013.7.JNS122340. Epub 2013 Sep 6.

PMID:
24010971
18.

Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results.

Senders JT, Muskens IS, Schnoor R, Karhade AV, Cote DJ, Smith TR, Broekman ML.

Acta Neurochir (Wien). 2017 Jan;159(1):151-167. doi: 10.1007/s00701-016-3028-5. Epub 2016 Nov 22. Review.

19.

5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement.

Widhalm G, Wolfsberger S, Minchev G, Woehrer A, Krssak M, Czech T, Prayer D, Asenbaum S, Hainfellner JA, Knosp E.

Cancer. 2010 Mar 15;116(6):1545-52. doi: 10.1002/cncr.24903.

20.

Use of fluorescence to guide resection or biopsy of primary brain tumors and brain metastases.

Marbacher S, Klinger E, Schwyzer L, Fischer I, Nevzati E, Diepers M, Roelcke U, Fathi AR, Coluccia D, Fandino J.

Neurosurg Focus. 2014 Feb;36(2):E10. doi: 10.3171/2013.12.FOCUS13464.

PMID:
24484248

Supplemental Content

Support Center